Latest News

Date Title Topic
05 Sep 2017 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML Haematologic malignancies - Anticancer agents & Biologic therapy
05 Sep 2017 ESMO 2017 Press Release: MIRO Trial: 3-year Outcomes Favour Laparoscopic Surgery for Oesophageal Cancer Gastrointestinal cancers
04 Sep 2017 Ribociclib Receives EU Approval as First-Line Treatment for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
04 Sep 2017 ESMO 2017 Press Release: ICON8 Trial Reaffirms Standard Dosing in Ovarian Cancer Chemo Gynaecologic malignancies
03 Sep 2017 ESMO 2017 Press Release: Study in Early Stage Breast Cancer Shows That Even Small Tumours Can Be Aggressive Breast cancer
02 Sep 2017 ESMO 2017 Press Release: Study Highlights Overuse of Tumour Marker Tests in Primary and Secondary Care Epidemiology/Etiology/Cancer Prevention
01 Sep 2017 FDA Approves Tisagenlecleucel for B-Cell ALL and Tocilizumab for Cytokine Release Syndrome Haematologic malignancies - Palliative and supportive care - Cancer Immunology and Immunotherapy
01 Sep 2017 ESMO 2017 Media Alert: Updated ESMO Magnitude of Clinical Benefit Scale Set to Evaluate Single-arm Studies
31 Aug 2017 Indels Provide Highly Immunogenic Neoantigens and May Be Potential Biomarkers of Immunotherapy Response Translational research - Cancer Immunology and Immunotherapy
31 Aug 2017 ESMO 2017 Press Release: IFCT-0302 results question role of CT-scan in NSCLC post-surgery follow-up Lung and other thoracic tumours
30 Aug 2017 NICE Issues Technology Appraisal Guidance on Olaratumab in Combination with Doxorubicin for Treating Advanced STS Sarcomas - Anticancer agents & Biologic therapy
30 Aug 2017 Media Alert: ESMO 2017 Poster and Oral Abstracts Published Online Tonight
29 Aug 2017 Adolescent and Young Adult Cancer Survivors Are Less Likely to Have HPV-Vaccination than Peers Cancer in Special Situations - Epidemiology/Etiology/Cancer Prevention
23 Aug 2017 Concept Paper on Development and Lifecycle of Personalised Medicines and Companion Diagnostics Personalised medicine - Bioethics, legal and economic issues
22 Aug 2017 FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL Haematologic malignancies - Anticancer agents & Biologic therapy